To provide clinical evidence of improved efficacy ("Good On" time) with optimizing immediate-release carbidopa-levodopa (IR CD-LD) or an extended-release CD-LD (IPX203) treatment.
No takes yet. Share an insight, caveat, or question.
Hauser et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: